Eyal Talor

Awards Nomination 20+ Million Readerbase

PMC/PubMed Indexed Articles

Maintenance and Intensification of Bivalent Oral Poliovirus Vaccine Use Prior to its Coordinated Global Cessation

MEFA (multiepitope fusion antigen)-Novel Technology for Structural Vaccinology, Proof from Computational and Empirical Immunogenicity Characterization of an Enterotoxigenic Escherichia coli (ETEC) Adhesin MEFA

Google Scholar citation report

Citations : 2327

Journal of Vaccines & Vaccination received 2327 citations as per Google Scholar report

Journal of Vaccines & Vaccination peer review process verified at publons

25+ Million Website Visitors

Indexed In

Academic Journals Database
Open J Gate
Genamics JournalSeek
JournalTOCs
China National Knowledge Infrastructure (CNKI)
Scimago
Ulrich's Periodicals Directory
RefSeek
Hamdard University
EBSCO A-Z
OCLC- WorldCat
Publons
MIAR
University Grants Commission
Geneva Foundation for Medical Education and Research
Euro Pub
Google Scholar

Useful Links

Share This Page

Tweets by Vaccine41931315

Open Access Journals

Eyal Talor

Department of Clinical Research CEL-SCI Corporation, Vienna, USA

Biography

Dr. Eyal Talor is currently Chief Scientific Officer. Prior to this, Dr. Talor was the Senior Vice President of Research and Manufacturing. He is a clinical immunologist with over 19 years of hands-on management of clinical research and drug development for immunotherapy applicationpre-clinical to Phase III, in the biopharmaceutical industry.